Abstract
Patients with immune-mediated inflammatory diseases (IMID) such as inflammatory bowel disease (IBD) on immunosuppressive and biologic therapies were largely excluded from SARS-CoV-2 mRNA vaccine trials. We thus evaluated post-mRNA vaccination adverse events (AE) in 246 vaccinated adults with IBD participating in a longitudinal vaccine registry. In general, AE frequency was similar to that reported in the general population. As in the general population, AE were more common among younger patients, and those with prior COVID-19. We additionally found that AE were less common in individuals receiving biologic therapy. Those with IBD and other IMID on these commonly prescribed therapies can be reassured that the AE risk is likely not increased, and may be reduced, while on biologics.
Competing Interest Statement
GB: none. DL: Consultant: Prometheus Bioscience. JF: none. SC: none. JB: Research funding from Janssen. DM: Consultant: Takeda, Boehringer Ingelheim, Palatin Technologies, Bridge Biotherapeutics, Pfizer, Gilead. Consultant and Stockholder: Prometheus Biosciences. GYM: Consultant: Abbvie, Boehringer-Ingelheim, Bristol-Meyers-Squibb, Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda, Techlab, Research funding from Pfizer, Crohns and Colitis Foundation.
Clinical Trial
observational study, not a clinical trial
Funding Statement
This study was supported by the The Leona M. and Harry B. Helmsley Charitable Trust, the Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, and the National Institute of Diabetes and Digestive and Kidney Disease Grants P01DK046763 and U01DK062413. This study has been additionally supported in part by the Cedars-Sinai Precision Health Initiative, the Erika J. Glazer Family Foundation, and through the Serological Sciences Network, grant NCI U54-CA260591.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by Cedars-Sinai IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Disclosures GB – none
DL – Consultant: Prometheus Bioscience
JF – none
SC – none
JB – Research funding from Janssen
DM - Consultant: Takeda, Boehringer Ingelheim, Palatin Technologies, Bridge Biotherapeutics, Pfizer, Gilead. Consultant and Stockholder: Prometheus Biosciences
GYM – Consultant: Abbvie, Boehringer-Ingelheim, Bristol-Meyers-Squibb/Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda, Techlab, Research funding from Pfizer, Crohn’s and Colitis Foundation
Funding: This study was supported by the The Leona M. and Harry B. Helmsley Charitable Trust, the Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, and the National Institute of Diabetes and Digestive and Kidney Disease Grants P01DK046763 and U01DK062413. This study has been additionally supported in part by the Cedars-Sinai Precision Health Initiative, the Erika J. Glazer Family Foundation, and through the Serological Sciences Network, grant NCI U54-CA260591.
Acquisition of data: GB, JB, DM, GM
Analysis and interpretation of data: all authors
Drafting of the manuscript: GM
Critical revision of the manuscript for important intellectual content: all authors
Statistical analysis: GB, DL
Obtained funding: JF, SC, DM, JB, GM
Technical, or material support: JF, SC
Study supervision: JB, DM, GM
Data Availability
Data are available in the manuscript and supporting files.